One‐compound‐multiple‐targets strategy to combat Alzheimer's disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The present one‐drug‐one‐target paradigm in drug discovery has been considered partially responsible for the more‐funding‐less‐drug predicament in modern pharmaceutical industry. To hit the multiple targets implicated in complex diseases, two strategies, based on multicomponent or single‐ingredient, are conceivable. Although the latter is more difficult to be fulfilled than the former, the recent progress made in the fight against Alzheimer's disease (AD) has brought us the first light of success of the latter strategy. In this review, both synthetic and natural multipotent agents are described, which hit two or more targets implicated in AD, e.g., acetylcholinesterase, monoamine oxidase, amyloid‐β, τ protein, metal ions and reactive oxygen species. Nevertheless, due to the potential risks in safety, absorbability and pharmacokinetics of synthetic multipotent agents, natural counterparts seem more promising in the future development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis
Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683 · cited 2×
“clioquinol) in treating AD [5,15] and the fact that some superoxide dismutase (SOD) mimetics are metal chelates, Ji et al.”
BackgroundPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336 · cited 1×
“However, recent in vitro and in vivo experiments revealed that curcumin can block Ab aggregation with high efficiency (IC50 < 1 lM) [21,22].”
BackgroundCurcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254 · cited 1×
“However, recent in vitro and in vivo experiments revealed that curcumin can block Ab aggregation with high efficiency (IC50 < 1 lM) [21,22].”
BackgroundCummings, J. L. (2004) · New England Journal of Medicine · doi:10.1056/nejmra040223 · Cited by 1,152
Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., MacGregor, L., Kiers, L., Cherny, R., Li, Q.-X., Tammer, A., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1685 · Cited by 988 · cited 1×
“clioquinol) in treating AD [5,15] and the fact that some superoxide dismutase (SOD) mimetics are metal chelates, Ji et al.”
BackgroundMulticomponent therapeutics for networked systems
Keith, C. T., Borisy, A. A., & Stockwell, B. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1609 · Cited by 769 · cited 2×
“One is called multicomponent therapeutic strategy, which incorporates two or more active ingredients in one drug [2].”
BackgroundPhenolic anti-inflammatory antioxidant reversal of Aβ-induced cognitive deficits and neuropathology
Frautschy, S. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00300-1 · Cited by 514
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185 · cited 1×
“Following the acceptance of the review, two interesting papers appeared [37,38], in which Youdim and coworkers reported that some designed iron chelators hold MAO-AB inhibitory activity and antioxidant effect, thus can serve as multipotent agents to combat AD and Parkinson s disease.”
Background
Cited by
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Coumarin hybrids as novel therapeutic agents
Sandhu, S., Bansal, Y., Silakari, O., & Bansal, G. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.032 · Cited by 296
Bolognesi, M. L., Cavalli, A., Valgimigli, L., Bartolini, M., Rosini, M., Andrisano, V., Recanatini, M., & Melchiorre, C. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701225u · Cited by 260
Rodríguez-Rodríguez, C., Telpoukhovskaia, M., & Orvig, C. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.03.008 · Cited by 151
Rochais, C., Lecoutey, C., Gaven, F., Giannoni, P., Hamidouche, K., Hedou, D., Dubost, E., Genest, D., Yahiaoui, S., Freret, T., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00115 · Cited by 129
Metadata
- Authors
- Zhang, H.-Y.
- Venue
- FEBS Letters
- Publisher
- Wiley
- Published
- 2005-09-20
- Volume
- 579
- Issue
- 24
- Pages
- 5260-5264
- ISSN
- 0014-5793 (ISSN-L)
- 1873-3468
- OpenAlex
- W2094994507
- Cited by
- 138
- References
- 10
- FWCI
- 4.59
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One‐compound‐multiple‐targets strategy to combat Alzheimer's disease. https://app.cochat.ai/papers/10.1016/j.febslet.2005.09.006
- The paper
- Zhang, H.-Y. (2005). One‐compound‐multiple‐targets strategy to combat Alzheimer's disease. FEBS Letters. https://doi.org/10.1016/j.febslet.2005.09.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.